The Institute for Clinical and Economic Review is planning to evaluate US commercial insurance policies for drugs that it considers to be reasonably priced to see how consistently fair prices are rewarded with favorable formulary coverage.
The study, which will focus on prior authorizations, marks an expansion of ICER’s traditional focus on drug value and prices to explore whether lower prices equal better insurance access. A report on the evaluation is scheduled to be issued in October and ICER plans to do the assessment on a yearly basis. The group released its
